This topic contains 0 replies, has 1 voice, and was last updated by 
MS News Today Moderator 1 month, 3 weeks ago.
-
Posts
-
Two years after its approval and with new data from ECTRIMS, Ocrevus is living up to its designation as a “game-changer,” Genentech’s Hideki Garren says. Read more here.
Do you agree that Ocrevus is a “game-changer” for people with MS?
You must be logged in to reply to this topic.
